Literature DB >> 21118400

Focal cortical dysplasia coexisting with diffuse astrocytoma in childhood: a case report and reappraisal of the glial component in archival FCD cases.

Kenta Masui1, Satoshi O Suzuki, Kimiaki Hashiguchi, Takato Morioka, Takashi Yoshiura, Tomio Sasaki, Toru Iwaki.   

Abstract

We report a rare case of focal cortical dysplasia (FCD) concurring with diffuse astrocytoma and arachnoid cyst, and also re-evaluate the glial component in archival FCD cases for the differential diagnosis of diffuse gliomas. A 7-year-old boy with a 9-month history of psychomotor seizures disclosed a hyperintense area accompanied by a cystic lesion in the left temporal lobe on MRI. The surgical specimen displayed dyslamination of the cortices and ectopic neurons in the white matter, associated with dysmorphic neurons, indicating FCD type IIA. Additionally, the lesion showed diffuse proliferation and infiltration of glial cells, immunopositive for infiltrating glioma markers (nestin, doublecortin, MAP-2e) and p53, and MIB-1 index was 2.0%. These findings indicated coexisting diffuse astrocytoma. Coexistence of diffuse glioma with FCD is unusual, but we often notice increased population of small glial cells in FCD lesions. Re-evaluation of archival FCD cases with diverse markers revealed that reactive microglia significantly proliferate in the white matter lesions. Therefore, a careful pathological assessment has to be made to define a rare case of diffuse glioma occurring in FCD.
© 2010 Japanese Society of Neuropathology.

Entities:  

Mesh:

Year:  2010        PMID: 21118400     DOI: 10.1111/j.1440-1789.2010.01173.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  1 in total

1.  The Frequency of Focal Cortical Dysplasia-Like Histologic Features Near Adult-Type Diffuse Gliomas.

Authors:  Mireille Bitar; Yevgen Chornenkyy; Margaret E Flanagan; Alicia Steffens; Kathleen McCortney; Craig Horbinski
Journal:  J Neuropathol Exp Neurol       Date:  2022-01-21       Impact factor: 3.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.